Sodium glucose co-transport 2 inhibitors for gout treatment.

Autor:	Somagutta MKR; Department of Family Medicine, Southern Illinois School of Medicine, Springfield, Illinois.; Avalon University School of Medicine, Willemstad, Curacao., Luvsannyam E; Avalon University School of Medicine, Willemstad, Curacao., Jain M; Saint James School of Medicine, Park Ridge, Illinois, USA., Cuddapah GV; Kamineni Academy of Medical Sciences and Research Center, Hyderabad, India., Pelluru S; Kamineni Academy of Medical Sciences and Research Center, Hyderabad, India., Mustafa N; The National Ribat University Khartoum, Sudan., Nasereldin DS; Ahfad University for Women, Omdurman, Sudan., Pendyala SK; Avalon University School of Medicine, Willemstad, Curacao., Jarapala N; Atlantic University School of Medicine, Gross Islet, St. Lucia., Padamati B; Atlantic University School of Medicine, Gross Islet, St. Lucia.
Jazyk:	angličtina
Zdroj:	Discoveries (Craiova, Romania) [Discoveries (Craiova)] 2022 Sep 30; Vol. 10 (3), pp. e152. Date of Electronic Publication: 2022 Sep 30 (Print Publication: 2022).
DOI:	10.15190/d.2022.11
Abstrakt:	Hyperuricemia remains the most prevalent cause of gout. Gout patients present with joint inflammation and uric acid crystals deposition manifesting as tophi. The association of gout with increased risk of insulin resistance, diabetes, metabolic disorders, increased cardiometabolic risk, and kidney disease is well established. These factors influence the treatment plan, and current treatment options have limited cardiovascular risk reduction. So the need for novel treatments with a broad range of coverage for the complications is warranted. Sodium-glucose co-transporter 2 inhibitors are novel drugs approved for treating type-2 diabetes. They prevent glucose reabsorption and lower serum uric acid levels. Recently few studies have studied their association with reducing the risk of gout. They may help address the gout related complications through their recorded benefit with weight loss, improved insulin resistance, and cardiovascular benefits in recent studies. . SGLT2-Is may be useful to reduce the risk of gout in individuals with type 2 diabetes. Limited literature is available on the safety and efficacy of these novel antidiabetic drugs in patients with gout. This review is aimed to summarize the current knowledge on the role and effectiveness of novel antidiabetic medication as an early therapeutic option in gout patients. Competing Interests: Conflict of interests: The authors declare no conflicts of interest. (Copyright © 2022, Somagutta MKR et al., Applied Systems and Discoveries Journals.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu